Depósito Digital de Documentos de la UAB Encontrados 1 registros  La búsqueda tardó 0.00 segundos. 
1.
13 p, 2.0 MB Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer / Garrido-Castro, Ana C. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ; Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ; Guo, Hao (Dana-Farber Cancer Institute. Division of Biostatistics, Department of Data Sciences) ; Ciruelos, Eva (Hospital 12 de Octubre (Madrid)) ; Bermejo, Begoña (CIBERONC-ISCIII. Clinic University Hospital, INCLIVA Biomedical Research Institute) ; Gavilá, Joaquin (Fundación Instituto Valenciano De Oncología) ; Serra, Violeta (VHIO) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paré, Laia (SOLTI Breast Cancer Research Group) ; Céliz, Pamela (SOLTI Breast Cancer Research Group) ; Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ; Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ; Savoie, Jennifer (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Xu, Zhan (Northern Arizona University. School of Communication) ; Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ; Krop, Ian E. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Solit, David B. (Memorial Sloan Kettering Cancer Center. Kravis Center for Molecular Oncology) ; Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ; Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ; Winer, Eric P. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Lin, Nancy U. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ; Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ; Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)  

Vea también: autores con nombres similares
37 Xu, Z.
1 Xu, Zhenfeng
1 Xu, Zheng
1 Xu, Zhihong
8 Xu, Zhikun
2 Xu, Zhongwei
1 Xu, Zhuwen
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.